1:40
CLL11 trial shows improved OS rates in CLL with obinutuzumab
Barbara Eichhorst
3:01
MM treatment in the US vs. Europe: multi-drug regimens & cellular therapies
Ola Landgren
1:32
iNNOVATE results: a prospective new standard of care for Waldenström’s
Meletios Dimopoulos
1:56
Randomized trials of pomalidomide combinations for MM
Meletios Dimopoulos
5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn
4:15
Advanced Hodgkin lymphoma: AHL2011 data update from EHA 2018
Olivier Casasnovas
3:42
Key factors in the tumor-tumor microenvironment relationship in myeloma
Bruno Paiva
3:31
Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma
Ramon Garcia-Sanz
5:35
Contemporary designs for multiple myeloma treatment
Gareth Morgan
2:18
New applications for MRD measurement in myeloma: MRD ‘over time’
Ola Landgren
1:56
Clinical trials investigating venetoclax combinations for AML
Andrew Wei
2:49
Improving the activity of BH3 mimetic venetoclax: a case study
Andrew Wei
0:52
The importance of MRD negativity as a predictive marker in CLL
Peter Hillmen
1:29
Outstanding results from CLARITY: a new CLL combination therapy
Peter Hillmen
1:16
Future improvements in developing CLL therapy
Peter Hillmen
2:30
Increasing AML clinical trial participation rates
Gail Roboz
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals